Anixa Biosciences, Inc. · NASDAQ:ANIX
Anixa Biosciences — Investor Presentation (September 2020)
16 slides from Anixa Biosciences's investor presentation, Sep 16, 2020
Slide 1: Anixa Biosciences
Aanixa BIOSCIENCES September 16, 2020 NASDAQ:ANIX Amit Kumar Chairman and CEO ak@anixa.com
Slide 2: Forward-Looking Statements
orward-Looking Statements Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa Biosciences’ current
Slide 3: Corporate Background
Corporate Background General & Financial e NASDAQ: ANIX ¢ Bay Area, CA Biotech ¢ Three high value programs Key Collaborators F’} Cleveland Clinic THE WISTAR INSTITUTE Aanixa Strategy: Low Cost Business Model ¢ Invent/in-license technology platforms © Develop technology with partners e Leverage exist
Slide 4: Three High Value Programs
Three High Value Programs Breast Cancer Vaccine *° Immunize against a-Lactalbumin to prevent Triple Negative Breast Cancer (TNBC) and other breast cancers * Worldwide license * Cleveland Clinic collaboration for IND and clinical trial * $6.2 MM DOD grant will fund pre-clinical work and two Ph 1 clin
Slide 5: Commercial Partnership and Monetization Strategy
Commercial Partnership and Monetization Strategy * Drug development is risky — We mitigate the risk by diversifying — We also work on programs that are relatively low cost * Our strategy is to monetize our programs, through licensing partnerships, once we have positive Phase 1, first in human data —
Slide 6: Breast Cancer Vaccine
Breast Cancer Vaccine Inventor and PI: Vincent K. Tuohy, Ph.D. Mort and Iris November Distinguished Chair in Innovative Cancer Research, Cleveland Clinic Retired Tissue Specific Protein a-LACTALBUMIN * Expressed at periods of life, but no longer expressed as we age Expressed only in the breast and o
Slide 7: Vaccination Prevents Breast Cancer
Vaccination Prevents Breast Cancer 100 “<= 80 = ® 60 iN a Ss 40 = = - 20 * Vaccinated e 100% of a-LACTALBUMIN vaccinated mice did not develop breast cancer Vaccinated mice did not exhibit autoimmune damage, while single T-cell infiltrates were seen in non-lactating breast tissue (arrows) Aanixa EFFE
Slide 8: Breast Cancer Vaccine Clinical Trial Plan
Breast Cancer Vaccine Clinical Trial Plan Funded by Department of Defense (DOD) Grant $6.2 MM Pre-Clinical Studies ° GLP Tox Phase 1a Trial ¢ IND filing a * TNBC patients who have Phase 1b Trial undergone standard of care ¢ Healthy women with BRCA1 * Will monitor pro-inflammatory mutations T-cell re
Slide 9: Summary: Breast Cancer Vaccine
Summary: Breast Cancer Vaccine KEY ATTRIBUTES MARKET OPPORTUNITY (Estimates) Prophylactic (preventative) vaccines are administered to all eligible, not the small number of sick patients “Cleveland Clinic collaboration \Y_DOD funded program; $6.2 Pre-clinical Expect reimbursement for this vaccine to
Slide 10: CAR-T Technology: Background & Opportunity
CAR-T Technology: Background & Opportunity CAR- Technology has made great inroads in B-Cell cancers * Durable responses (50-80% of patients) * Multibillion dollar valuations and big pharma deals > Novartis - First approved product by FDA e Kymriah for ALL- Acute Lymphoblastic Leukemia 2 Second appro
Slide 11: Anixa's Unique CER-T Approach for Solid Tumors
Anixa’s Uni ue CER-TA roach for Solid Tumors Novartis, JUNO, KITE and others working on B-Cell cancers Cancerous scFv-antibody fragment engineered into T-cell Aanixa B-cell CD19 protein (antigen) <_— Anixa’s CAR-T Program for Ovarian Cancer FSHR- Follicle Stimulating Hormone Receptor Chimeric Endocr
Slide 12: FSHR ONLY Expressed in Ovaries and Testis
FSHR ONLY Expressed in Ovaries and Testis *In Healthy Humans* 6 0.00255 a g 0.002- ; 8 0.0015 al aa ¢ FSHR expressed on the blood vessels ooo" \ of many TUMORS 4 ‘\ £ 0.001- \ Ns % ¢ This therapy will be anti-angiogenic # 0.0005- \ for many types of cancer, enabling a uw \ ; = g “ i portfolio of the
Slide 13: Our Magic Bullet
Our Magic Bullet Many tumors have blood vessels where FSHR is expressed even though healthy tissue does not show such expression o Physiologically, FSHR must be helpful in enabling tumors to create vasculature o Outside of the tumor margin, FSHR on blood vessels disappears Our FSHR targeted CAR-T ma
Slide 14: Summary: CAR-T Program
Summary: CAR-T Program * Exclusive worldwide license from The Wistar Institute o Tested human CAR-T in immunocompromised mice against human ovarian cancer o Tested murine CAR-T in immunocompetent mice against murine ovarian cancer o Tested human CAR-T in immunocompromised mice against human breast c
Slide 15: Covid-19 Program
Covid-19 Program Initiated April 20, 2020 with partner OntoChem, GmbH — Virtual Screening (1.2 BB compounds) SARS-CoV-2 Virtual Screening & Scoring Fy \s of 1.2 Billion Compounds = Targets: Main Protease (M?®), Endoribonuclease (NSP-15) Enzymes Ss ¢ In Silico Hits — Utilize Molecular Modeling, Scree
Slide 16: Anixa's Value-Creating Near-Term Milestones
Anixa’s Value-Creating Near-Term Milestones Breast Cancer Vaccine Filing of IND for clinical trials- 2020 Approval of IND by FDA Patient recruitment First patient dosed and initiation of clinical trial Clinical Data Release Covid-19 Therapeutics Identify additional potential compounds Results of in
Anixa Biosciences — Investor Presentation (September 2020) on 6ix